Arkolith/Insider Trading/NGM/Form 4

Woodhouse David J

Chief Executive Officer, DirectorNGM BIOPHARMACEUTICALS INC (NGM) · full profile →Form 4 · filed Apr 8, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
13
2 non-derivative · 11 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 5, 2024Tender(U)24K——0
Apr 5, 2024Tender(U)98K——0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 5, 2024Disposed to issuer(D)87K——0
Apr 5, 2024Disposed to issuer(D)58K——0
Apr 5, 2024Disposed to issuer(D)500K——0
Apr 5, 2024Disposed to issuer(D)200K——0
Apr 5, 2024Disposed to issuer(D)400K——0
Apr 5, 2024Disposed to issuer(D)450K——0
Apr 5, 2024Disposed to issuer(D)500K——0
Apr 5, 2024Disposed to issuer(D)382K——0
Apr 5, 2024Disposed to issuer(D)500K——0
Apr 5, 2024Disposed to issuer(D)95K——0
Apr 5, 2024Disposed to issuer(D)255K——0

Transaction Codes

U
See SEC Form 4 code table
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-24-042609) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML